GE HealthCare Technologies Inc. filings document formal disclosures for a medical technology and diagnostics company, including Form 8-K reports on results of operations and financial condition, material agreements, capital-structure matters, and governance changes. Recent current reports include earnings releases, a senior unsecured revolving credit facility, and board-related disclosures.
The company’s proxy materials describe annual-meeting matters, director elections, board committee assignments, executive compensation, equity awards, and shareholder voting procedures. GEHC filings also provide formal context for segment performance, liquidity arrangements, credit covenants, and governance matters tied to its healthcare technology, software, and pharmaceutical diagnostics businesses.
Dodge & Cox, a California-based investment manager, reports beneficial ownership of 37,864,164 shares of GE Healthcare Technologies Inc. common stock, representing 8.3% of the class. It holds sole voting power over 35,801,954 shares and sole dispositive power over all 37,864,164 shares.
The firm states that its clients have the right to receive dividends and sale proceeds on these shares. Dodge & Cox Stock Fund holds 24,247,113 shares, or 5.3% of the outstanding common stock as part of the reported position.
GE HealthCare Technologies Inc. reorganized its reporting structure by combining its Imaging and Advanced Visualization Solutions businesses into a new Advanced Imaging Solutions (AIS) segment and now reports three segments: AIS, Pharmaceutical Diagnostics (PDx), and Patient Care Solutions (PCS), plus an Other category for HealthCare Financial Services. Exhibit 99 provides recast unaudited historical financial information under this structure, which has no impact on previously reported financial statements.
Recast data show AIS generated $14,599 million of revenue in 2025 and $3,640 million in the quarter ended March 31, 2026; total company revenue was $20,625 million in 2025 and $5,131 million in that quarter. For the March 31, 2026 quarter, segment EBIT was $479 million for AIS, $197 million for PDx, and $10 million for PCS, with income before income taxes of $505 million.
The company also presented non‑GAAP Organic revenue measures, excluding acquisitions, dispositions, and foreign currency effects. Total Organic revenue grew 3.5% year over year in 2025 and 2.9% for the quarter ended March 31, 2026, with PDx reporting the highest Organic growth rates among the segments.
GE HealthCare Technologies Inc. reported Q2 2026 total revenues of $5,295 million, up from $5,007 million a year earlier, and first-half revenues of $10,425 million. Q2 net income attributable to GE HealthCare was $561 million (diluted EPS $1.24) versus $486 million ($1.06); first-half net income was $950 million ($2.08 diluted EPS) versus $1,049 million ($2.29).
Advanced Imaging Solutions generated Q2 revenues of $3,771 million, Pharmaceutical Diagnostics $843 million, and Patient Care Solutions $675 million. The company closed the $2,293 million cash acquisition of Intelerad, adding $1,629 million of goodwill and $845 million of definite-lived intangibles funded mainly with senior notes and a $650 million term loan.
Cash and equivalents fell to $2,108 million at June 30, 2026 from $4,515 million at the start of the year, reflecting acquisition spending and $300 million of share repurchases. Total borrowings were $10,093 million. GE HealthCare recognized $129 million of pre-tax tariff refund benefits and recorded $76 million in restructuring charges year-to-date.
GE HealthCare Technologies Inc. reported Q2 2026 revenues of $5.3 billion, up 5.7% with 3.5% organic growth. Net income attributable to GE HealthCare was $561 million, a 10.6% margin; adjusted EBIT was $750 million with a 14.2% margin. Diluted EPS was $1.24 and adjusted EPS $1.13, both benefiting from tariff refunds and a lower tax rate.
Organic orders rose 11.1%, yielding a book-to-bill of 1.15x and a $23.9 billion backlog. Advanced Imaging Solutions and Pharmaceutical Diagnostics grew strongly, while Patient Care Solutions declined and is under strategic review. Q2 free cash flow was $68 million; cash was $2.1 billion and debt $10.1 billion. The company repurchased 3.3 million shares for $200 million, declared a $0.035 dividend, and reaffirmed 2026 guidance for 3.0%–4.0% organic revenue growth, 15.4%–15.7% adjusted EBIT margin, adjusted EPS of $4.80–$5.00, and about $1.6 billion of free cash flow.
GE HealthCare Technologies Inc. reported preliminary, unaudited second quarter 2026 results. The company expects to report total revenue of $5,295 million for the three months ended June 30, 2026, up , with organic revenue of $5,182 million, reflecting 3.5% organic growth. Management also expects year-over-year growth in diluted EPS and Adjusted EPS, above its prior expectation, and reaffirmed full-year 2026 guidance.
GE HealthCare announced a leadership transition as Chief Financial Officer Jay Saccaro will resign for a role outside the medical technology industry, remaining through August 14, 2026 to support a smooth transition. George Newcomb, Controller and Chief Accounting Officer, will become interim CFO effective that date while retaining his current roles. The company emphasized that these financial results are preliminary and subject to change, with full second quarter results to be discussed on July 29, 2026.
GE HealthCare Technologies Inc. director Kevin Lobo reported an open-market purchase of 10,000 shares of common stock at $64.18 per share. After this transaction, he directly owns a total of 14,363 shares of GE HealthCare common stock.
GE HealthCare Technologies Inc. reported that Philip Rackliffe, CEO of AIS, received a grant of 16,458 restricted stock units tied to its common stock. Each unit entitles him to one share at settlement. Half of the units are scheduled to vest on May 15, 2028, and the remaining half on May 15, 2029.
Following this compensation-related award, Rackliffe directly holds 43,187 shares of GE HealthCare common stock. The grant carries no cash exercise price and represents long-term equity-based compensation rather than an open-market stock purchase.
GE HealthCare Technologies Inc. executive Jeannette Bankes, CEO of Patient Care Solutions, reported a routine share withholding related to equity compensation. On May 15, 2026, 5,535 shares of common stock were withheld at $62.67 per share to cover tax obligations from vesting restricted stock units.
This was a tax-withholding disposition, not an open-market sale. Following the transaction, Bankes directly held 38,357 shares of GE HealthCare common stock.
GE HEALTHCARE TECHNOLOGIES INC. Schedule 13G/A shows 31,312,064 shares beneficially owned as of 03/31/2026, representing 6.9% of the outstanding common stock. The filing reports 29,686,614 shares as sole voting power and 31,312,064 shares as sole dispositive power.
The disclosure states these holdings are held on behalf of Dodge & Cox clients, including registered investment companies and managed accounts. The form is signed by the firm’s Chief Compliance Officer on 05/14/2026.
GE HealthCare Technologies Inc. — Capital Research Global Investors filed an amended Schedule 13G reporting beneficial ownership of 21,114,633 shares of common stock, or 4.6% of the 456,290,143 shares believed to be outstanding. The amendment identifies sole voting power for 21,106,720 shares and sole dispositive power for 21,114,633. The filing is signed by a Capital Research officer on 05/11/2026.